RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Beam Therapeutics P/E 2024

Beam Therapeutics P/E

-3.66

Beam Therapeutics Dividend yield

Ticker

BEAM

ISIN

US07373V1052

WKN

A2PY7P

As of May 2, 2024, Beam Therapeutics's P/E ratio was -3.66, a -80.67% change from the -18.93 P/E ratio recorded in the previous year.

The Beam Therapeutics P/E history

Beam Therapeutics Aktienanalyse

What does Beam Therapeutics do?

Beam Therapeutics Inc. is a leading company in genome editing and was founded in 2018. The company is headquartered in Cambridge, Massachusetts, USA, and aims to develop and bring innovative genome editing technologies to the market. Beam Therapeutics' business model is based on developing groundbreaking technologies that improve and simplify genome editing in living cells. These technologies are used in medicine, agriculture, and other industries to cure diseases, increase crop yields, and improve quality of life. Beam Therapeutics is led by an experienced and competent team composed of leading scientists, engineers, and businesspeople in the industry. The company collaborates closely with industry and academic partners to develop innovative solutions for genome editing. Beam Therapeutics has several business units focused on the development of genome editing technologies and products. One of these business units is the development of CRISPR technologies (Clustered Regularly Interspaced Short Palindromic Repeats), which allow for precise and effective modification of DNA. Beam Therapeutics employs Prime Editors, a new technology that enables the removal, insertion, or replacement of specific DNA sequences. Another important business area for Beam Therapeutics is the development of novel gene therapy products. This involves repairing or removing disease-causing genes in the body to accelerate or even achieve complete recovery. The gene therapy products being developed by Beam Therapeutics have the potential to save lives and provide a long-term solution for certain diseases such as cancer, viral infections, and specific genetic disorders. The company collaborates closely with universities, hospitals, and other institutions to drive the development of gene therapy products. Beam Therapeutics strives to revolutionize the gene therapy industry and improve the treatment of diseases through genome editing. Overall, Beam Therapeutics has an impressive track record and has experienced strong growth in recent years. The company has successfully completed multiple funding rounds to advance its research and development and has hired many talented employees to realize its vision. In summary, Beam Therapeutics is a medical technology company specializing in the development of groundbreaking genome editing technologies and products. The company aims to revolutionize genome editing in medicine, agriculture, and other industries and have a positive impact on people's lives. Beam Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Beam Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of Beam Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Beam Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Beam Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Beam Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Beam Therapeutics Stock

What is the price-to-earnings ratio of Beam Therapeutics?

The price-earnings ratio of Beam Therapeutics is currently -3.66.

How has the price-earnings ratio of Beam Therapeutics changed compared to last year?

The price-to-earnings ratio of Beam Therapeutics has increased by -80.67% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Beam Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Beam Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Beam Therapeutics affect the company?

An increase in the price-earnings ratio of Beam Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Beam Therapeutics affect the company?

A decrease in the price-earnings ratio of Beam Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Beam Therapeutics?

Some factors that influence the price-earnings ratio of Beam Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Beam Therapeutics pay?

Over the past 12 months, Beam Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Beam Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Beam Therapeutics?

The current dividend yield of Beam Therapeutics is .

When does Beam Therapeutics pay dividends?

Beam Therapeutics pays a quarterly dividend. This is distributed in the months of December, March, June, March.

How secure is the dividend of Beam Therapeutics?

Beam Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Beam Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Beam Therapeutics located?

Beam Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Beam Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Beam Therapeutics from 3/3/2014 amounting to 0.225 USD, you needed to have the stock in your portfolio before the ex-date on 2/4/2014.

When did Beam Therapeutics pay the last dividend?

The last dividend was paid out on 3/3/2014.

What was the dividend of Beam Therapeutics in the year 2023?

In the year 2023, Beam Therapeutics distributed 0 USD as dividends.

In which currency does Beam Therapeutics pay out the dividend?

The dividends of Beam Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Beam Therapeutics

Our stock analysis for Beam Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Beam Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.